Immune consequences of anti-angiogenic therapy in renal cell carcinoma

Klaudia K. Brodaczewska; Cezary Szczylik; Claudine Kieda

doi:10.5114/wo.2018.73878

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Contemporary Oncology

1/2018

Send email

Copy url:

abstract:

Review paper

Immune consequences of anti-angiogenic therapy in renal cell carcinoma

Klaudia K. Brodaczewska

,

Cezary Szczylik

,

Claudine Kieda

Contemp Oncol (Pozn) 2018; 22 (1A): 14–22

DOI: https://doi.org/10.5114/wo.2018.73878

Online publish date: 2018/03/08

View full text Get citation

PlumX metrics:

Current therapies of renal cell carcinoma (RCC), a highly vascularised tumour, mostly rely on anti-angiogenic treatment options. These include tyrosine kinase inhibitors (TKIs) and anti-VEGF monoclonal antibodies. Although these strategies aim at restraining vascularisation to control tumour growth, the effects of such therapies are much wider, as affecting the vessel structure deeply modifies the microenvironment of the tumour mass. The aim of this review is to provide an overview of current knowledge on the global effects of anti-angiogenic treatment, mostly TKIs, on the shaping of the immune component of the RCC microenvironment. The data supporting the modification of immunity by anti-angiogenic therapies are collected to reveal the potential of angiogenesis modulation as a strategy for the adjuvant anti-cancer approach in immunotherapy.

keywords:

Immune consequences of anti-angiogenic therapy in renal cell carcinoma

Klaudia K. Brodaczewska , Cezary Szczylik , Claudine Kieda

renal cell carcinoma, angiogenesis, tyrosine kinase inhibitors, vessel normalisation

Klaudia K. Brodaczewska

,

Cezary Szczylik

,

Claudine Kieda